Article
Medicine, General & Internal
Javier Perez Stachowski, David Rial Crestelo, Ana Moreno Zamora, Noemi Cabello, Pablo Ryan, Nuria Espinosa Aguilera, Otilia Bisbal, Maria Jesus Vivancos Gallego, Maria Jose Nunez, Jesus Troya, Montserrat Dominguez, Julian Olalla Sierra
Summary: This study evaluated the efficacy and safety of TAF/FTC/EVG-c as first-line treatment in HIV-1 infected naive patients. The results showed that this drug had comparable efficacy to pivotal clinical trial data and had a good safety profile in patients with advanced HIV disease.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Erik Schwiebert, Yi Wang, Ranhui Xi, Katarzyna Choma, John Streiff, Linda J. Flammer, Natasha Rivers, Mehmet Hakan Ozdener, Robert F. Margolskee, Carol M. Christensen, Nancy E. Rawson, Peihua Jiang, Paul A. S. Breslin
Summary: An identified compound has shown promise in blocking bitter taste responses to a specific drug in human taste bud epithelial cells, reducing bitterness perception in human sensory testing. This combined approach can successfully discover molecules for blocking perceived bitterness of pharmaceuticals, potentially improving medical compliance.
MOLECULAR PHARMACOLOGY
(2021)
Article
Microbiology
Yu-Shan Huang, Chien-Yu Cheng, Hsin-Yun Sun, Shu-Hsing Cheng, Po-Liang Lu, Chen-Hsiang Lee, Yuan-Ti Lee, Hung-Chin Tsai, Chia-Jui Yang, Chun-Eng Liu, Bo-Huang Liou, Shih-Ping Lin, Sung-Hsi Huang, Mao-Wang Ho, Hung-Jen Tang, Chien-Ching Hung
Summary: Data on the durability of TAF-containing antiretroviral therapy in maintaining HBV viral suppression among HIV/HBV-coinfected patients are limited. This study filled the gap by enrolling 274 participants and assessing viral loads and serology markers through 96 weeks. Results showed high rates of viral suppression and improvements in renal parameters, while fasting lipids increased and BMD stabilized at 96 weeks after the switch.
MICROBIOLOGY SPECTRUM
(2023)
Article
Medicine, General & Internal
Shahin Lockman, Sean S. Brummel, Lauren Ziemba, Lynda Stranix-Chibanda, Katie McCarthy, Anne Coletti, Patrick Jean-Philippe, Ben Johnston, Chelsea Krotje, Lee Fairlie, Risa M. Hoffman, Paul E. Sax, Sikhulile Moyo, Nahida Chakhtoura, Jeffrey S. A. Stringer, Gaerolwe Masheto, Violet Korutaro, Haseena Cassim, Blandina T. Mmbaga, Esau Joao, Sherika Hanley, Lynette Purdue, Lewis B. Holmes, Jeremiah D. Momper, Roger L. Shapiro, Navdeep K. Thoofer, James F. Rooney, Lisa M. Frenkel, K. Rivet Amico, Lameck Chinula, Judith Currier
Summary: This study compared the safety and efficacy of three antiretroviral regimens started in pregnancy. The dolutegravir-containing regimens had superior virological efficacy at delivery compared with the efavirenz-containing regimen and the dolutegravir, emtricitabine, and tenofovir disoproxil fumarate regimen. The dolutegravir, emtricitabine, and tenofovir alafenamide fumarate regimen had the lowest frequency of composite adverse pregnancy outcomes and of neonatal deaths.
Article
Infectious Diseases
Daniel Podzamczer, Arkaitz Imaz, Ana Lopez-Lirola, Hernando Knobel, Mar Masia, Chiara Fanciulli, Cristina Hernandez, Maria Lagarde, Angela Gutierrez, Adria Curran, Luis Morano, Marta Montero-Alonso, Jesus Troya, Raul Rigo, Maria Casadella, Antonio Navarro-Alcaraz, Fernando Ardila, Mariona Parera, Enrique Bernal, Patricia Echeverria, Vicente Estrada, Carmen Hidalgo-Tenorio, Juan Macias, Paula Prieto, Joaquin Portilla, Eulalia Valencia, Maria Jesus Vivancos, Antonio Rivero
Summary: This study evaluated the efficacy and safety of a switching strategy using bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily treatment-experienced people living with HIV. The results showed that this regimen was effective and well-tolerated, potentially improving convenience and long-term treatment success.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Immunology
Yu-Shan Huang, Chien-Yu Cheng, Bo-Huang Liou, Po-Liang Lu, Shu-Hsing Cheng, Yuan-Ti Lee, Chun-Eng Liu, Hsin-Yun Sun, Chia-Jui Yang, Hung-Jen Tang, Shih-Ping Lin, Mao-Wang Ho, Sung-Hsi Huang, Hung-Chin Tsai, Chen-Hsiang Lee, Chien-Ching Hung
Summary: Switching to E/C/F/TAF maintained viral suppression of both HIV and HBV, improved proteinuria and bone mineral density, but led to increased lipid levels in HIV/HBV-coinfected patients at week 48.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
(2021)
Article
Immunology
Liqin Sun, Yun He, Liumei Xu, Fang Zhao, Yang Zhou, Lukun Zhang, Qiaoli Peng, Haitao Zhang, Qiuyue Zhang, Tingzhi Cao, Ying Song, Siyuan Wang, Man Rao, Xinyun Jia, Xiaoning Liu, Jing Zhou, Bin Ju, Hui Wang, Jiaye Liu
Summary: Comparing the evolution of blood lipids between HIV patients receiving different antiretroviral treatments, it was found that patients treated with E/C/F/TAF had higher risks of dyslipidemia.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
(2022)
Article
Endocrinology & Metabolism
Jason J. Schafer, Matty Zimmerman, Ciara Walshe, Jesse Cerankowski, Ayako Shimada, Scott W. Keith
Summary: Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in antiretroviral therapy may lead to metabolic changes and increased risk of cardiovascular disease, particularly in cholesterol levels.
Article
Multidisciplinary Sciences
Ines Mendoza, Alicia Lazaro, Alfredo Espinosa, Lorenzo Sanchez, Ana Maria Horta, Miguel Torralba
Summary: This study shows that dolutegravir plus lamivudine (2-DR) is not as effective as bictegravir/emtricitabine/tenofovir alafenamide (3-DR) in treating HIV-1. However, the durability and safety of 2-DR are similar to 3-DR.
Article
Virology
Stephanie Cox, Nicolas Margot, Christian Callebaut
Summary: TAF, a prodrug of TFV, achieves higher intracellular levels of active metabolite TFV-DP while reducing TFV systemic exposure compared to TDF. In vitro activity evaluation shows that TAF has higher resistance against K65R-containing clinical isolates of HIV-1 compared to TDF.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Immunology
Qing-Min Liu, Yi-Yu He, Li-Li Liu, Li-Kun Wang
Summary: The study demonstrated that exosomes derived from CHB patients treated with TAF and TAF-treated macrophages exhibited potent antiviral activities against HBV infection, with lncRNA HOTTIP playing a key role in mediating this antiviral effect.
JOURNAL OF INFLAMMATION RESEARCH
(2021)
Article
Immunology
Blake Max, Patricia DeMarais
Summary: Some HIV medications may lead to excessive weight gain, but it is still unknown who is at greatest risk and if the weight gain is reversible. More research is needed to understand and mitigate this potential long-term complication of antiretroviral therapy.
INTERNATIONAL JOURNAL OF STD & AIDS
(2021)
Article
Pharmacology & Pharmacy
G. J. Gatto, A. Krovi, L. Li, I. Massud, A. Holder, J. Gary, P. Mills, J. Mitchell, E. Luecke, Z. R. Demkovich, W. Heneine, J. G. Garcia-Lerma, M. A. Marzinke, R. M. Brand, C. W. Dobard, L. M. Johnson, A. van der Straten
Summary: This paper describes a subcutaneous implant for the long-acting delivery of tenofovir alafenamide (TAF) and evaluates its safety and pharmacokinetics in animal models. The implant effectively delivered TAF for 3-6 months, but also resulted in local adverse events. Despite these events, the implant maintained a constant drug release profile.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Health Care Sciences & Services
Baptiste Sellem, Basma Abdi, Minh Le, Roland Tubiana, Marc-Antoine Valantin, Sophie Seang, Luminita Schneider, Antoine Faycal, Gilles Peytavin, Cathia Soulie, Anne-Genevieve Marcelin, Christine Katlama, Valerie Pourcher, Romain Palich
Summary: In this observational study, researchers evaluated the effectiveness of administering bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 5 or 4 days a week in maintaining viral suppression in people living with HIV. The study included 85 patients who started intermittent B/F/TAF between November 28, 2018, and July 30, 2020. The results showed a high success rate in terms of both virological success and strategy success, indicating that the intermittent dosing of B/F/TAF could effectively control HIV replication while reducing exposure to antiretroviral therapy (ART).
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Pharmacology & Pharmacy
G. J. Gatto, A. Krovi, L. Li, I. Massud, A. Holder, J. Gary, P. Mills, J. Mitchell, E. Luecke, Z. R. Demkovich, W. Heneine, J. G. Garcia-Lerma, M. A. Marzinke, R. M. Brand, C. W. Dobard, L. M. Johnson, A. Van der Straten
Summary: This paper describes a subcutaneous, reservoir-style implant designed for the long-acting delivery of tenofovir alafenamide (TAF) and documents its safety and pharmacokinetics assessment in different animal models. Despite local adverse events, the implant effectively released tenofovir diphosphate (TFV-DP), supporting the continued development of this drug delivery platform.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Roberto Castoldi, Francesca Bai, Sabrina Caberlon, Daris Ferrari, Alessia Moro, Gian Marco Podda, Antonella d'Arminio Monforte, Giulia Carla Marchetti
INTERNAL AND EMERGENCY MEDICINE
(2022)
Article
Infectious Diseases
Francesca Bai, Daniele Tomasoni, Camilla Falcinella, Diletta Barbanotti, Roberto Castoldi, Giovanni Mule, Matteo Augello, Debora Mondatore, Marina Allegrini, Andrea Cona, Daniele Tesoro, Gianmarco Tagliaferri, Ottavia Vigano, Elisa Suardi, Camilla Tincati, Tomaso Beringheli, Benedetta Varisco, Chiara Luridiana Battistini, Kyrie Piscopo, Elena Vegni, Alessandro Tavelli, Stefano Terzoni, Giulia Marchetti, Antonella D'Arminio Monforte
Summary: This study explored the association between female gender and long COVID syndrome, and found that female gender, older age, and active smoking were associated with a higher risk of long COVID.
CLINICAL MICROBIOLOGY AND INFECTION
(2022)
Article
Infectious Diseases
Joao Marques-Gomes, Matthew J. Salt, Rita Pereira-Neto, Franca S. Barteldes, Vera Gouveia-Barros, Alexandre Carvalho, Antonella d'Arminio-Monforte, Alethse De-la-Torre-Rosas, Amy Harris, Catarina Esteves, Carcom Maor, Cristina Mora, Carla Oliveira, Cristina Sousa, Douglas D. Richman, Esteban Martinez, Fabio Cota-Medeiros, Filipa Gramacho, Georg M. N. Behrens, Graca Goncalves, Helena Farinha, Isabel Nabais, Ines Vaz-Pinto, Juan Sierra-Madero, Joaquim Sousa-Gago, John Thornhill, Jose Vera, Maja Erceg-Tusek, Margarida Tavares, Miguel Vasconcelos, Nuno Fernandes, Nicola Gianotti, Nienke Langebeek, Paulo Anjos, Raquel Couto, Ricardo Fernandes, Reena Rajasuriar, Rosario Serrao, Shaun Watson, Teresa Branco, Tiago Teixeira, Vicente Soriano
Summary: This study aims to address the lack of routine, standardized data in HIV care by establishing a set of standardized HIV care outcome indicators. These outcomes will include patient-reported outcomes, clinician-reported measures, and administratively reported outcomes, with standardized measures included.
Article
Medicine, General & Internal
Antonella Cingolani, Alessandro Tavelli, Franco Maggiolo, Annalisa Perziano, Annalisa Saracino, Francesca Vichi, Massimo Cernuschi, Giovanni Guaraldi, Eugenia Quiros-Roldan, Antonella Castagna, Andrea Antinori, Antonella d'Arminio Monforte
Summary: Treatment burden is a multidimensional concept that has been poorly explored in people living with HIV (PLHIV). A recent survey found that one out of five PLHIV experienced a high level of treatment and disease burden. Factors associated with high burden included younger age, lower satisfaction with antiretroviral therapy (ART), the need for better communication with the treating physician, and self-perceived lower overall health status.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Immunology
Antonella D'Arminio Monforte, Alessandro Tavelli, Sara De Benedittis, Francesca Bai, Camilla Tincati, Lidia Gazzola, Ottavia Vigano, Marina Allegrini, Debora Mondatore, Daniele Tesoro, Diletta Barbanotti, Giovanni Mule, Roberto Castoldi, Anna De Bona, Teresa Bini, Davide Chiumello, Stefano Centanni, Sabrina Passarella, Nicola Orfeo, Giulia Marchetti, Alessandro Cozzi-Lepri
Summary: This observational study examined the protective effect of vaccination against progression after hospital admission for COVID-19. The results showed that fully vaccinated individuals had a 50% reduced risk of in-hospital death and mechanical ventilation/death compared to unvaccinated individuals.
Letter
Infectious Diseases
Angelo Roberto Raccagni, Elena Bruzzesi, Daniele Calzavara, Pietro Vinti, Massimo Cernuschi, Simona Bossolasco, Anna De Bona, Roberto Rossotti, Antonella D'Arminio Monforte, Antonella Castagna, Silvia Nozza
Article
Virology
Valeria Bono, Camilla Tincati, Lorena Van den Bogaart, Elvira Stefania Cannizzo, Roberta Rovito, Matteo Augello, Anna De Bona, Antonella D'Arminio Monforte, Laura Milazzo, Giulia Marchetti
Summary: HIV-HCV co-infected individuals have higher levels of immune cell activation and gamma-globulins even after treatment, which may be associated with the risk of hepatic and extrahepatic complications.
Review
Virology
Massimo Fasano, Maria Cristina Poliseno, Jose Ramon Fiore, Sergio Lo Caputo, Antonella D'Arminio Monforte, Teresa Antonia Santantonio
Summary: This article discusses the management of liver disease in patients with HIV/HBV coinfection and summarizes the current and future therapeutic options for treating chronic hepatitis B in this setting.
Article
Food Science & Technology
Paola Ciceri, Valeria Bono, Lorenza Magagnoli, Matteo Sala, Antonella D'Arminio Monforte, Andrea Galassi, Alessandra Barassi, Giulia Marchetti, Mario Cozzolino
Summary: Patients with chronic kidney disease (CKD) are more susceptible to COVID-19 infection. This study investigated the accumulation of harmful mediators in CKD patients during COVID-19 and found a tendency to accumulate harmful cytokines, which was associated with mortality outcomes.
Article
Infectious Diseases
Matteo Augello, Valeria Bono, Roberta Rovito, Camilla Tincati, Giulia Marchetti
Summary: This review discusses the complex interplay between HIV and SARS-CoV-2, with a special focus on the immune responses to SARS-CoV-2 natural infection and vaccination in PLWH. The study found that poor immunovirological control is the major driver of weak immune responses to SARS-CoV-2 infection/vaccination and worse COVID-19 outcomes in PLWH.
CURRENT HIV/AIDS REPORTS
(2023)
Article
Infectious Diseases
Roberta Gagliardini, Patrizia Lorenzini, Alessandro Cozzi-Lepri, Alessandro Tavelli, Vanni Borghi, Laura Galli, Gianmarco Tagliaferri, Franco Maggiolo, Cristina Mussini, Antonella Castagna, Antonella d'Arminio Monforte, Andrea Antinori
Summary: This study aimed to investigate the impact of previous virological failures on the virological efficacy of Dolutegravir (DTG) + lamivudine (3TC) combination therapy. The study found that patients with previous failures had a higher risk of viral rebound compared to those without failures.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2023)
Article
Biochemistry & Molecular Biology
Andrea Galassi, Paola Ciceri, Valeria Bono, Lorenza Magagnoli, Matteo Sala, Luisa Artioli, Roberta Rovito, Mohamad Hadla, Vaibhav Yellenki, Antonella D'Arminio Monforte, Camilla Tincati, Mario Cozzolino, Giulia Marchetti
Summary: A cytokine storm plays a crucial role in the pathogenesis of severe COVID-19 infection, and certain biomarkers have been linked to mortality. Chronic kidney disease (CKD) is identified as a risk factor for severe COVID-19. This study investigated the association between specific biomarkers and mortality in COVID-19 patients, and examined the differences in patients with estimated glomerular filtration rate (eGFR) higher or lower than 45 mL/min. The results showed that patients with lower eGFR had higher levels of GDF-15, CD-25, and RAGE, and these biomarkers were significantly elevated in non-survivors and patients requiring ventilation. GDF-15 quartiles were independently associated with mortality risk, with higher quartiles indicating a higher risk. The association between GDF-15 quartiles and mortality risk was stronger in patients with lower eGFR. These findings suggest the potential of exploring the inhibitory effect of the GDF-15 signaling pathway in CKD.
Article
Microbiology
Robertoy Rossotti, Daniele Calzavara, Massimo Cernuschi, Federico D'Amico, Anna De Bona, Roberto Repossi, Davide Moschese, Simona Bossolasco, Alessandro Tavelli, Camilla Muccini, Giovanni Mule, Antonella d'Arminio Monforte
Summary: Mpox is a zoonotic disease that is traditionally endemic to Africa, but the 2022-2023 outbreak has seen a significant increase in cases in non-endemic countries, leading to it being declared an international public health emergency. The reasons for this global spread, particularly through sexual transmission among MSM, are still not fully understood, but the presence of asymptomatic carriers may play a role.
Article
Biology
Diletta Barbanotti, Camilla Tincati, Alessandro Tavelli, Andrea Santoro, Matteo Sala, Teresa Bini, Anna De Bona, Antonella d'Arminio Monforte, Giulia Carla Marchetti
Summary: Late diagnosis of HIV infection is a significant issue with negative consequences for individuals and communities. HIV screening based on HIV indicator conditions (HIVICs) has emerged as a useful strategy to identify cases beyond high-risk behaviors. In Milan, Italy, a hospital-based screening campaign named ICEBERG was conducted between 2019 and 2021, resulting in a 3.8% prevalence of HIV among the 520 enrolled subjects, most of whom had viral hepatitis or mononucleosis-like syndrome. The findings highlight the importance of educational interventions to improve clinicians' awareness and suggest the need for a combined approach to achieve early HIV diagnosis.
Article
Oncology
Lauren Greenberg, Lene Ryom, Elzbieta Bakowska, Ferdinand C. Wit, Heiner C. L. Bucher, Dominique L. Braun, Andrew Phillips, Caroline Sabin, Antonella d'Arminio Monforte, Robert Zangerle, Colette Smith, Stephane De Wit, Fabrice Bonnet, Christian Pradier, Cristina Mussini, Camilla Muccini, Joerg J. Vehreschild, Jennifer Hoy, Veronica M. Svedhem, Jose M. Miro, Jan-Christian Wasmuth, Peter M. Reiss, Josep M. Llibre, Nikoloz Chkhartishvili, Christoph I. Stephan, Camilla Hatleberg, Bastian Neesgaard, Lars Peters, Nadine Jaschinski, Nikos Dedes, Elena Kuzovatova, Marc Van Der Valk, Marianna Menozzi, Clara Lehmann, Kathy Petoumenos, Harmony Garges, Jim Rooney, Lital D. Young, Jens D. Lundgren, Loveleen Bansi-Matharu, Amanda Mocroft, RESPOND D A D Study Grp
Summary: Cancer incidence rates remained stable overall from 2006 to 2021, but there were changes in the rates of specific types of cancer among people with HIV. AIDS-defining cancers and infection-related cancers decreased, while non-AIDS-defining cancers, smoking-related cancers, and BMI-related cancers increased. These findings emphasize the importance of prevention strategies for reducing the incidence of non-AIDS-defining cancers, smoking-related cancers, and BMI-related cancers.